Role of tranexamic acid in reducing perioperative blood loss in abdominal oncosurgeries in group of patients aged between 25-75years.

To compare the doses of tranexamic acid for maximum reduction in perioperative blood loss in abdominal oncosurgeries( A Randomized Trial) - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/069240

Enrollment

Registered

2024-06-19

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C19- Malignant neoplasm of rectosigmoidjunction

Interventions

Intervention1: Inj. Tranexamic acid bolus 10mg/kg and infusion @ 1ml/kg/hr: patients will be given inj. tranexamic acid bolus @ 10mg/kg intravenously before incision, followed by infusion @ 1mg/kg/hr

Eligibility

Inclusion criteria

Inclusion criteria: ASA I,II,III Age between 25 years-75 years undergoing abdominal oncosurgeries

Exclusion criteria

Exclusion criteria: Refusal to participate in study Contraindication to the drug ASA IV,V,VI patients

Design outcomes

Primary

Measure	Time frame
To find the maximum decrease in perioperative blood loss using two different dosing regimens of tranexamic acid.Timepoint: To find the maximum decrease in perioperative blood loss using two different dosing regimens of tranexamic acid by assessing blood loss at the end of surgery, 12, 48 hours after surgery and patients hemoglobin @ 6, 12, 24 hours after surgery	—

Secondary

Measure	Time frame
(i)To compare two dosing regimens of tranexamic acid in terms of perioperative blood transfusion requirements and in first 48 hours. (ii)To compare in terms of post op Hb level at 12, 24 and 48 hours post tranexamic acid bolus and infusion doses respectivelyTimepoint: The comparison of perioperative blood requirement and Hb values at 12, 24 and 48 hours.	—

Countries

India

Contacts

Public ContactShweta Mahajan

Indira Gandhi Medical College,Shimla

shwetamahajan437@gmail.com9418040187

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026